Dataset Information


CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

ABSTRACT: Cereblon (CRBN), a substrate receptor of the E3 ubiquitin ligase complex CRL4CRBN, is the target of the immunomodulatory drugs lenalidomide and pomalidomide. Recently, it was demonstrated that binding of these drugs to CRBN promotes the ubiquitination and subsequent degradation of two common substrates, transcription factors Aiolos and Ikaros. Here we report that the pleiotropic pathway modifier CC-122, a new chemical entity termed pleiotropic pathway modifier binds CRBN and promotes degradation of Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) and T cells in vitro, in vivo and in patients, resulting in both cell autonomous as well as immunostimulatory effects. In DLBCL cell lines, CC-122-induced degradation or shRNA mediated knockdown of Aiolos and Ikaros correlates with increased transcription of interferon stimulated genes (ISGs) independent of interferon α, β, γ production and/or secretion and results in apoptosis in both ABC and GCB-DLBCL cell lines. Our results provide mechanistic insight into the cell of origin independent anti-lymphoma activity of CC-122, in contrast to the ABC subtype selective activity of lenalidomide. Microarray analysis of the OCI-LY10 activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) cell line treated with the compound CC-122 for 18 hours

ORGANISM(S): Homo sapiens  

SUBMITTER: Matthew Trotter   Patrick Hagner  Anita Gandhi  Courtney G Havens  Celia Fontanillo 

PROVIDER: E-GEOD-75420 | ArrayExpress | 2015-11-26



Similar Datasets

2012-08-16 | E-GEOD-33012 | ArrayExpress
2011-09-30 | E-GEOD-31451 | ArrayExpress
2011-09-30 | E-GEOD-31421 | ArrayExpress
2016-03-09 | E-GEOD-61693 | ArrayExpress
2014-05-13 | E-GEOD-57554 | ArrayExpress
| GSE93984 | GEO
2018-12-14 | PXD009380 | Pride
2015-05-19 | E-GEOD-66770 | ArrayExpress
2009-06-01 | GSE11902 | GEO
| GSE22900 | GEO